Please login to the form below

Not currently logged in
Email:
Password:

AZD1222

This page shows the latest AZD1222 news and features for those working in and with pharma, biotech and healthcare.

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

In an interim analysis, the vaccine – also known as AZD1222 – demonstrated a vaccine efficacy of 79% at preventing symptomatic COVID-19, as well as 100% efficacy at preventing severe disease and ... Although the US trial administered two doses of

Latest news

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...